In Boston, MA at the Society for Laboratory Automation and Screening (SLAS) annual International Conference and Exhibition, Depixus has been awarded the prestigious Ignite Award for their revolutionary MAGNA™ technology. This cutting-edge company was one of just 16 companies selected to participate in the SLAS2024 Innovation AveNEW program, which highlights start-ups and emerging companies within the conference.
MAGNA One is based on magnetic force spectroscopy, allowing high-throughput analysis of dynamic biomolecular interactions. It is the first technology to offer real-time measurements from thousands of individual molecules simultaneously, making it particularly useful for exploring challenging targets such as RNA and protein-protein interactions. By providing valuable insights into disease mechanisms and accelerating the development of novel therapeutics, MAGNA One is poised to revolutionize the life sciences industry.
Depixus CEO Gordon Hamilton was thrilled about winning the Ignite Award, emphasizing the company’s innovative technology and its potential to impact the understanding and treatment of diseases where new treatments are urgently needed. Chief Commercial Officer Steve Klose added that this award came at a significant moment for Depixus, coinciding with the launch of their technology access program and commercial rollout of MAGNA One. For more information about Depixus or MAGNA One, visit depixus.com or contact Steve Klose at firstname.lastname@example.org.